866-997-4948(US-Canada Toll Free)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Aug 2012

Category :

Diabetes

No. of Pages : 335 Pages


Type 1 Diabetes (Juvenile Diabetes) Pipeline Review, H2 2012

Global Markets Directs, \'Type 1 Diabetes (Juvenile Diabetes) Pipeline Review, H2 2012\', provides an overview of the Type 1 Diabetes (Juvenile Diabetes) therapeutic pipeline. This report provides information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes). \'Type 1 Diabetes (Juvenile Diabetes) Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Type 1 Diabetes (Juvenile Diabetes).
  • A review of the Type 1 Diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Type 1 Diabetes (Juvenile Diabetes) pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Type 1 Diabetes (Juvenile Diabetes) therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Type 1 Diabetes (Juvenile Diabetes) Therapeutic Products under Development, Key Players in Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Type 1 Diabetes (Juvenile Diabetes) Pipeline Overview, Type 1 Diabetes (Juvenile Diabetes) Pipeline, Type 1 Diabetes (Juvenile Diabetes) Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Type 1 Diabetes (Juvenile Diabetes) Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Type 1 Diabetes (Juvenile Diabetes) 12
Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Development by Companies 14
Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Products under Development by Companies 28
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Products under Investigation by Universities/Institutes 33
Companies Involved in Type 1 Diabetes (Juvenile Diabetes) Therapeutics Development 37
Bristol-Myers Squibb Company 37
Osiris Therapeutics, Inc. 38
Sanofi-Aventis 39
Eli Lilly and Company 40
Inovio Biomedical Corporation 41
MedImmune LLC 42
Taisho Pharmaceutical Co., Ltd. 43
Novo Nordisk A/S 44
Takeda Pharmaceutical Company Limited 45
SkyePharma PLC 46
BioLineRx, Ltd. 47
Biocon Limited 48
Kissei Pharmaceutical Co., Ltd. 49
Merck Serono S.A. 50
Hadasit Medical Research Services & Development Ltd 51
Biodel Inc. 52
MannKind Corporation 53
Halozyme Therapeutics 54
Evotec Aktiengesellschaft 55
Genfit 56
Living Cell Technologies Limited 57
Oramed Pharmaceuticals, Inc. 58
Lexicon Pharmaceuticals, Inc. 59
Flamel Technologies S.A. 60
NeoStem, Inc. 61
XOMA Ltd. 62
Lipoxen PLC 63
SemBiosys Genetics Inc. 64
Uni-Bio Science Group Ltd. 65
Kamada Ltd. 66
DiaMedica Inc. 67
Affimed Therapeutics AG 68
Axxam SpA 69
ActogeniX NV 70
Bayhill Therapeutics, Inc. 71
Phosphagenics Limited 72
Artielle ImmunoTherapeutics, Inc. 73
MacroGenics, Inc. 74
ApoImmune, Inc. 75
DiaKine Therapeutics, Inc. 76
EpiVax, Inc. 77
Kineta, Inc. 78
Andromeda Biotech Ltd. 79
AIM Therapeutics Inc. 80
Txcell SA 81
TcL Pharma SAS 82
Versartis, Inc. 83
NOXXON Pharma AG 84
Fate Therapeutics, Inc. 85
Immunomod, LLC 86
Immunocore Limited. 87
Provid Pharmaceuticals, Inc. 88
Novocell, Inc. 89
Tolera Therapeutics, Inc. 90
Medistem, Inc. 91
Exsulin Corporation 92
DiAthegen, LLC 93
NasVax Ltd. 94
REGiMMUNE Corporation 95
Adocia 96
S-Evans Biosciences, Inc. 97
Cebix Incorporated 98
PharmaIN Corporation 99
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Assessment 100
Assessment by Monotherapy Products 100
Assessment by Combination Products 101
Assessment by Route of Administration 102
Assessment by Molecule Type 105
Drug Profiles 108
Dapagliflozin - Drug Profile 108
BHT-3021 - Drug Profile 110
Teplizumab - Drug Profile 112
Teplizumab - Drug Profile 114
Ryzodeg - Drug Profile 116
Prochymal - Drug Profile 118
FT-105 - Drug Profile 120
IN-105 - Drug Profile 121
LX4211 - Drug Profile 122
EVT 770 - Drug Profile 124
GFT679 - Drug Profile 125
DiaPep277 - Drug Profile 126
Afrezza - Drug Profile 128
ORMD-0801 - Drug Profile 130
VGX-1027 - Drug Profile 132
ActoBiotics For Type 1 Diabetes - Drug Profile 133
DM-199 - Drug Profile 134
MD707 - Drug Profile 135
ApoFasL - Drug Profile 136
VRS-808 - Drug Profile 137
TS-071 - Drug Profile 138
AIM-501 - Drug Profile 139
UNI-rE-4 - Drug Profile 140
Exsulin - Drug Profile 142
DT 22669 - Drug Profile 144
Tresiba - Drug Profile 145
Diabecell - Drug Profile 147
IM-ASN - Drug Profile 149
Anakinra - Drug Profile 150
TPM Insulin - Drug Profile 151
GAD-Alum - Drug Profile 153
SuliXen - Drug Profile 154
AFM-15 - Drug Profile 155
Neulasta - Drug Profile 156
Etanercept + Islet Transplantation - Drug Profile 157
KGT-1681 - Drug Profile 158
Proleukin + Rapamune - Drug Profile 160
Kineret - Drug Profile 161
Abatacept + Islet Transplantation - Drug Profile 163
Kv1.3 Blocker - Drug Profile 164
Belatacept - Drug Profile 165
XOMA 052 - Drug Profile 166
Glibenclamide - Drug Profile 168
Lantus - Drug Profile 169
NPH Insulin - Drug Profile 170
Teplizumab - Drug Profile 171
Islet Stem Cells + Mesenchymal Stem Cells - Drug Profile 172
BCG Vaccine - Drug Profile 173
Diabetes Suppressive Dendritic Cell Vaccine - Drug Profile 174
Autologous CD34 + Stem Cells - Drug Profile 175
LY 2605541 - Drug Profile 177
Rilonacept - Drug Profile 179
Canakinumab - Drug Profile 180
Islet Autoantigen-Derived Peptide Vaccine - Drug Profile 181
Intranasal Insulin Vaccine - Drug Profile 182
Sitagliptin + Pantoprazole - Drug Profile 184
Thymoglobulin + Neulasta - Drug Profile 186
Antithymocyte Globulin - Drug Profile 187
Islet Transplant + LEA29Y + Daclizumab + Mycophenolate Mofetil - Drug Profile 188
Teplizumab - Drug Profile 190
NN1218 - Drug Profile 191
Deoxyspergualin + Islet Transplantation - Drug Profile 192
Analog Insulin-PH20 - Drug Profile 194
Linjeta - Drug Profile 195
Alpha-1 Antitrypsin - Drug Profile 197
Lipitor - Drug Profile 199
Victoza - Drug Profile 200
Diamyd - Drug Profile 201
Islet Transplant + Sirolimus + Tacrolimus + Daclizumab + Sulfamethoxazole + Ganciclovir + Trimethoprim + Pentamidine - Drug Profile 202
Islet Transplantation - Drug Profile 204
Metformin - Drug Profile 205
RTLs For Type 1 Diabetes - Drug Profile 206
ORMD 0801 - Drug Profile 207
Allogeneic Islets Of Langerhans Transplant + Raptiva + Sirolimus + Anti-Thymocyte Globulin - Drug Profile 208
CTLA-4 Ig - Drug Profile 210
Leptin - Drug Profile 211
Aralast NP - Drug Profile 213
Taurine - Drug Profile 214
Glassia - Drug Profile 215
Umbilical Cord Mesenchymal Stem Cells - Drug Profile 216
Pioglitazone - Drug Profile 218
Atorvastatin - Drug Profile 219
New Formulation Insulin Glargine - Drug Profile 220
New Formulation Insulin Glargine - Drug Profile 222
TAK-329 - Drug Profile 224
Kv1.3 Inhibitors - Drug Profile 225
RGI-3010 - Drug Profile 226
Januvia - Drug Profile 227
Tregs Expanded Using Anti-CD3/Anti-CD28 Beads + IL-2 - Drug Profile 228
Autologous Bone Marrow Mesenchymal Stem Cells Transplantation - Drug Profile 230
LY 2963016 - Drug Profile 231
Islet Transplantation + LEA29Y + Basiliximab + Mycophenolate Mofetil - Drug Profile 232
Fenofibrate - Drug Profile 234
SKP-1052 - Drug Profile 235
Anti-aCD3 Mab - Drug Profile 236
HSP70 Peptides - Drug Profile 238
Cannabidiol - Drug Profile 239
Drug For Diabetes - Drug Profile 240
SBS-1000 - Drug Profile 241
HinsBet - Drug Profile 243
Leukothera - Drug Profile 245
Ersatta - Drug Profile 246
PGC GLP-1 - Drug Profile 249
PGC Basal Insulin - Drug Profile 250
Drug For Type I Diabetes - Drug Profile 251
ShK-186 - Drug Profile 252
Insulin + Metformin - Drug Profile 254
FT201 - Drug Profile 256
NN1953 - Drug Profile 257
PPI C19-A3 - Drug Profile 258
Endometrial Regenerative Cells - Drug Profile 259
Pro-Islet - Drug Profile 260
ImmTAC Targeting Islet Cell - Drug Profile 262
LY2963016 + Insulin Lispro - Drug Profile 264
Athelos - Drug Profile 266
MesoStem - Drug Profile 267
Glucostem - Drug Profile 268
MenSCs - Drug Profile 269
AS605240 - Drug Profile 270
Drug Targeting DQ2/DQ8 - Drug Profile 272
EDP 10 - Drug Profile 273
Stem Cells - Drug Profile 274
Islet Transplants - Drug Profile 275
Pancreatic Islet Transplantation - Drug Profile 276
Non-Depleting Antibodies - Drug Profile 277
NOX-G15 - Drug Profile 278
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Drug Profile Updates 279
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Discontinued Products 310
Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Dormant Products 312
Type 1 Diabetes (Juvenile Diabetes) Product Development Milestones 317
Featured News & Press Releases 317

Appendix 325
Methodology 325
Coverage 325
Secondary Research 325
Primary Research 325
Expert Panel Validation 325
Contact Us 326
Disclaimer 326

List of Table


Number of Products Under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2012 21
Products under Development for Type 1 Diabetes (Juvenile Diabetes) Comparative Analysis, H2 2012 22
Number of Products under Development by Companies, H2 2012 24
Number of Products under Development by Companies, H2 2012 (Contd..1) 25
Number of Products under Development by Companies, H2 2012 (Contd..2) 26
Number of Products under Development by Companies, H2 2012 (Contd..3) 27
Number of Products under Development by Companies, H2 2012 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 32
Comparative Analysis by Late Stage Development, H2 2012 33
Comparative Analysis by Mid Clinical Stage Development, H2 2012 34
Comparative Analysis by Early Clinical Stage Development, H2 2012 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 36
Products under Development by Companies, H2 2012 37
Products under Development by Companies, H2 2012 (Contd..1) 38
Products under Development by Companies, H2 2012 (Contd..2) 39
Products under Development by Companies, H2 2012 (Contd..3) 40
Products under Development by Companies, H2 2012 (Contd..4) 41
Products under Investigation by Universities/Institutes, H2 2012 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 45
Bristol-Myers Squibb Company, H2 2012 46
Osiris Therapeutics, Inc., H2 2012 47
Sanofi-Aventis, H2 2012 48
Eli Lilly and Company, H2 2012 49
Inovio Biomedical Corporation, H2 2012 50
MedImmune LLC, H2 2012 51
Taisho Pharmaceutical Co., Ltd., H2 2012 52
Novo Nordisk A/S, H2 2012 53
Takeda Pharmaceutical Company Limited, H2 2012 54
SkyePharma PLC, H2 2012 55
BioLineRx, Ltd., H2 2012 56
Biocon Limited, H2 2012 57
Kissei Pharmaceutical Co., Ltd., H2 2012 58
Merck Serono S.A., H2 2012 59
Hadasit Medical Research Services & Development Ltd, H2 2012 60
Biodel Inc., H2 2012 61
MannKind Corporation, H2 2012 62
Halozyme Therapeutics, H2 2012 63
Evotec Aktiengesellschaft, H2 2012 64
Genfit, H2 2012 65
Living Cell Technologies Limited, H2 2012 66
Oramed Pharmaceuticals, Inc., H2 2012 67
Lexicon Pharmaceuticals, Inc., H2 2012 68
Flamel Technologies S.A., H2 2012 69
NeoStem, Inc., H2 2012 70
XOMA Ltd., H2 2012 71
Lipoxen PLC, H2 2012 72
SemBiosys Genetics Inc., H2 2012 73
Uni-Bio Science Group Ltd., H2 2012 74
Kamada Ltd., H2 2012 75
DiaMedica Inc., H2 2012 76
Affimed Therapeutics AG, H2 2012 77
Axxam SpA, H2 2012 78
ActogeniX NV, H2 2012 79
Bayhill Therapeutics, Inc., H2 2012 80
Phosphagenics Limited, H2 2012 81
Artielle ImmunoTherapeutics, Inc., H2 2012 82
MacroGenics, Inc., H2 2012 83
ApoImmune, Inc., H2 2012 84
DiaKine Therapeutics, Inc., H2 2012 85
EpiVax, Inc., H2 2012 86
Kineta, Inc., H2 2012 87
Andromeda Biotech Ltd., H2 2012 88
AIM Therapeutics Inc., H2 2012 89
Txcell SA, H2 2012 90
TcL Pharma SAS, H2 2012 91
Versartis, Inc., H2 2012 92
NOXXON Pharma AG, H2 2012 93
Fate Therapeutics, Inc., H2 2012 94
Immunomod, LLC, H2 2012 95
Immunocore Limited., H2 2012 96
Provid Pharmaceuticals, Inc., H2 2012 97
Novocell, Inc., H2 2012 98
Tolera Therapeutics, Inc., H2 2012 99
Medistem, Inc., H2 2012 100
Exsulin Corporation, H2 2012 101
DiAthegen, LLC, H2 2012 102
NasVax Ltd., H2 2012 103
REGiMMUNE Corporation, H2 2012 104
Adocia, H2 2012 105
S-Evans Biosciences, Inc., H2 2012 106
Cebix Incorporated, H2 2012 107
PharmaIN Corporation, H2 2012 108
Assessment by Monotherapy Products, H2 2012 109
Assessment by Combination Products, H2 2012 110
Assessment by Stage and Route of Administration, H2 2012 113
Assessment by Stage and Molecule Type, H2 2012 116
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Drug Profile Updates 288
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Discontinued Products 319
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Discontinued Products (Contd..1) 320
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Dormant Products 321
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Dormant Products (Contd..1) 322
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Dormant Products (Contd..2) 323
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Dormant Products (Contd..3) 324
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Dormant Products (Contd..4) 325

List of Chart


Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2012 21
Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 29
Late Stage Products, H2 2012 33
Mid Clinical Stage Products, H2 2012 34
Early Clinical Stage Products, H2 2012 35
Discovery and Pre-Clinical Stage Products, H2 2012 36
Assessment by Monotherapy Products, H2 2012 109
Assessment by Combination Products, H2 2012 110
Assessment by Route of Administration, H2 2012 111
Assessment by Stage and Route of Administration, H2 2012 112
Assessment by Molecule Type, H2 2012 114
Assessment by Stage and Molecule Type, H2 2012 115

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *